Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.

Temporary MTX suspension improves immunogenicity of influenza vaccines in RA patients

18 Apr 2018

In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.

The study randomly assigned 156 patients to the MTX-continue group and 160 patients to the MTX-hold group (temporary MTX discontinuation for 2 weeks) after receipt of the 2016–2017 quadrivalent seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria.

The primary outcome was frequency of satisfactory vaccine response, defined as 4-fold increase in haemagglutination inhibition (HI) antibody titre at 4 weeks after vaccination. Secondary endpoints included seroprotection rate (ie, HI titre ≥1:40) and fold change in antibody titres.

Significantly more patients in MTX-hold group achieved satisfactory vaccine response than in the MTX-continue group (75.5 percent vs 54.5 percent; p<0.001).

Results for seroprotection rate were also more favourable in the MTX-hold group vs the MTX-continue group for all four antigens (H1N1: difference, 10.7 percent; H3N2: difference, 15.9 percent; B-Yamagata: difference, 13.7 percent; B-Victoria: difference, 14.7 percent).

Finally, patients in the MTX-hold group showed a higher fold-increase in the antibody titres for all four influenza antigens (p<0.05 for all). Change in disease activity was similar between the MTX-continue and MTX-hold groups.

The vaccine was well tolerated, with adverse events profile similar between the MTX-continue and MTX hold groups.

Compared with healthy individuals, patients with RA carry a greater infectious disease burden due to immune dysfunction associated with the underlying autoimmunity and immunosuppressive treatment, researchers said. This increased susceptibility to infection underscores the importance of vaccinating patients for preventable infectious agents and temporary suspending MTX treatment to increase the immunogenicity of vaccines.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.